Popular on EntSun
- IRF Builders Forum Brings Global Leaders to Washington, D.C. to Advance Religious Freedom Through Cooperative Engagement - 227
- BillBoards Inc. Hits the Road with God Bless America Tour and Reality Series Now Streaming on Tubi TV - 173
- databahn Launches GenAI Sales Intelligence Platform to Revolutionize Fortune 500 and Global 2000 Account Research - 134
- Byrd Davis Alden & Henrichson Launches Independence Day Safe Ride Initiative with 500 Free Uber Credits - 126
- The ITeam Ranked on Channel Partners 2025 MSP 501—Tech Industry's Most Prestigious List of Managed Service Providers Worldwide - 119
- Revolutionary Blockchain Platform Okh Finance Announces Okh Finance(OKKH) Token Launch to Transform Global Asset Leasing Market - 119
- Agreement to Supply US-Based Defense Provider with Thin-Film Solar Tech for Orbital Application; Ascent Solar Technologies, Inc. (N A S D A Q: ASTI) - 117
- NYC Leadership Strategist Stacie Selise Launches Groundbreaking 4S Framework Series to Redefine Executive Excellence - 113
- Easton & Easton, LLP Files Suit Against The Dwelling Place Anaheim & Vineyard USA Over Abuse Allegations - 107
- The Sessions Studios Secures $300 Million Commitment to Launch World-Class Studio and 15-Film Global Slate - 106
Similar on EntSun
- Pixel Studio Productions Launches Same-Day Headshots in Houston
- SeedList Launching Institutional Crypto Crowdfunding Project to Empower Retail Investors and Disrupt the VC-Dominated Crypto Fundraising Landscape
- California Family Launches Billboard to Reach "Pardon Czar" Alice Marie Johnson
- Sumter Landing Dental Care Launches Summer Special on Full Mouth Reconstruction
- Seligson Law Launches New Website to Support Cannabis Businesses in California and New York
- CelluHeal™ Launches Full Line of Advanced Wound Dressings for Online Purchase in the USA, Canada, and Beyond
- Yasmine Roulleau named Managing Director in Vancouver, Canada
- $53 Million Company Valuation Investment with Majority Acquisition Option, Plus New Stock CUSIP Supporting Brand Transition of Fan Engagement Company
- $14M Deal with Famed David Lloyd for Sports, Entertainment & Gaming, AI Powered Fan Engagement Company; New Stock CUSIP; Creating Shareholder Value
- Dr. Harmon Completes Prestigious Zygomatic Implant Residency in Brazil
Whistleblower Was Fired By Shire Pharmaceuticals After Reporting Violations
EntSun News/11003582
Holding Big Pharma Accountable As Required Under The Controlled Substances Act
BOSTON & OAKLAND, N.J. - EntSun -- Dr. Vincent Politio, a former Shire Pharmaceuticals employee, filed a Whistleblower complaint after being terminated by Shire Pharmaceuticals. Dr. Polito was fired by Shire on August 24, 2016 immediately after he reported the violation of laws to the United States Attorney's Office in Washington, D.C.
Dr. Polito claims he was asked to investigate and create a DEA-compliant Suspicious Order Monitoring system (SOM) to monitor and report suspicious orders. Dr. Polito alleges his concerns of Shire being out of compliance with the DEA's regulations were repeatedly downplayed and ignored by his superiors. He claims executives interfered with his work by changing his presentations to other key executives.
Dr. Polito claims he was terminated from his project in the summer of 2015, after he, a consultant, and the head of the SOM project, Wes Graham, visited Shire's U.S. Distribution facility in Lexington Kentucky. There he alleges they discovered drugs that were marked for destruction were not verified by either counting or weighing the pill bottles' contents.
Dr. Polito also claims to have discovered that Shire's internal company sales data did not match sales data reported to the DEA. The Court filings state Dr. Polito reported his discovery to his superiors and other executives and was soon removed from the project.
In January 2016, he alleges that over the objection of his supervisor, Walter Mullikin, he again reported the alleged violations of the DEA regulations to the then Chief Compliance Officer, Jeffrey Rosenbaum. Court documents show Dr. Polito was then forcibly placed on leave and was never allowed to return.
More on EntSun News
Dr. Polito was ultimately terminated on August 24, 2016 immediately after meeting with the U.S. Attorney's office in Washington, D.C. to report numerous violations of laws and Shire's failure to monitor Suspicious Orders of drugs and report them to the DEA.
In August 2018 he filed this wrongful termination suit in Massachusetts Superior Court alleging he was fired in violation of Public Policy for whistleblowing activities. The case was originally filed in August 2018 with an amended complaint filed in December 2018. Shire Pharmaceuticals filed a Motion to Dismiss which was rejected by the Court.
Shire Pharmaceuticals filed a Motion for Summary Judgment in early 2023. The Motion was heard on July 11, 2023. The case is in the hands of Judge Christopher K. Barry-Smith, Middlesex County Superior Court in Massachusetts under case number 1881CV02440.
What's the Importance of DEA Regulations and Potential Consequences for Violation?
The public's health is at stake. At the time of the Complaint, Shire manufactured and distributed Adderall and Vyvanse. Considered amphetamines, both drugs are listed as Scheduled II controlled substances because they have a "high potential for abuse" and can cause "severe psychic or physical and or psychological dependence."
Under Federal law, Shire is required to maintain "effective control" against these drugs from falling into the wrong hands. For that reason, Shire and other organizations in the pharmaceutical industry are required under the Controlled Substances Act (CSA), to create internal automated systems to monitor and track suspicious orders of drugs like Adderall and Vyvanse and report them to the DEA.
More on EntSun News
What's the importance of the corporate integrity agreement? Was this a corporate Coverup?
In September 2014, as Dr. Polito began his work on Suspicious Order Monitoring, Shire agreed to pay $56.5 million as part of a settlement agreement with the Federal Government for alleged violations in their promotion of Adderall and Vyvanse. As part of the settlement, Shire entered into a five-year Corporate Integrity Agreement (CIA).
According to Section III of this Agreement Shire was required to establish and maintain a U.S. Compliance Program. The Agreement requires the chief compliance officer to be responsible for monitoring the day-to-day compliance activities as well as reporting obligations under the CIA. The CIA was signed by then Chief Compliance Officer Caroline H. West.
What was the economic environment at the time of Polito's employment? (mergers and inversions)
In 2014 Shire was engaged with Abbvie in a reverse acquisition for $54 billion. The deal fell through with Shire receiving $1.6 billion for Abbvie's failed attempt. In February 2015 Shire acquired NPS Pharmaceuticals for $5.2 billion. And in June 2016, just as Shire decided to terminate Dr. Polito, Shire acquired Baxalta for $32 billion. Shire was acquired by Takeda in 2019 for $62 billion.
Does this create SEC problems?
The Securities and Exchange Commission (SEC) requires public companies to report information on significant pending lawsuits. An initial review of Shire's 10-k filings for the years 2018- 2021 is silent on Dr. Polito's lawsuit. Whether a lawsuit that alleges violations of DEA's Suspicious Orders regulations and exposes Shire to the type of fines or potential for loss of license qualifies as significant under SEC regulations is something to consider.
Dr. Polito claims he was asked to investigate and create a DEA-compliant Suspicious Order Monitoring system (SOM) to monitor and report suspicious orders. Dr. Polito alleges his concerns of Shire being out of compliance with the DEA's regulations were repeatedly downplayed and ignored by his superiors. He claims executives interfered with his work by changing his presentations to other key executives.
Dr. Polito claims he was terminated from his project in the summer of 2015, after he, a consultant, and the head of the SOM project, Wes Graham, visited Shire's U.S. Distribution facility in Lexington Kentucky. There he alleges they discovered drugs that were marked for destruction were not verified by either counting or weighing the pill bottles' contents.
Dr. Polito also claims to have discovered that Shire's internal company sales data did not match sales data reported to the DEA. The Court filings state Dr. Polito reported his discovery to his superiors and other executives and was soon removed from the project.
In January 2016, he alleges that over the objection of his supervisor, Walter Mullikin, he again reported the alleged violations of the DEA regulations to the then Chief Compliance Officer, Jeffrey Rosenbaum. Court documents show Dr. Polito was then forcibly placed on leave and was never allowed to return.
More on EntSun News
- California Family Launches Billboard to Reach "Pardon Czar" Alice Marie Johnson
- Performance Slots Available: Collision Course Concert Series Heads to Atlanta, Tampa & Brooklyn
- Rent Like A Champion Acquires CollegeWeekends
- Sumter Landing Dental Care Launches Summer Special on Full Mouth Reconstruction
- Seligson Law Launches New Website to Support Cannabis Businesses in California and New York
Dr. Polito was ultimately terminated on August 24, 2016 immediately after meeting with the U.S. Attorney's office in Washington, D.C. to report numerous violations of laws and Shire's failure to monitor Suspicious Orders of drugs and report them to the DEA.
In August 2018 he filed this wrongful termination suit in Massachusetts Superior Court alleging he was fired in violation of Public Policy for whistleblowing activities. The case was originally filed in August 2018 with an amended complaint filed in December 2018. Shire Pharmaceuticals filed a Motion to Dismiss which was rejected by the Court.
Shire Pharmaceuticals filed a Motion for Summary Judgment in early 2023. The Motion was heard on July 11, 2023. The case is in the hands of Judge Christopher K. Barry-Smith, Middlesex County Superior Court in Massachusetts under case number 1881CV02440.
What's the Importance of DEA Regulations and Potential Consequences for Violation?
The public's health is at stake. At the time of the Complaint, Shire manufactured and distributed Adderall and Vyvanse. Considered amphetamines, both drugs are listed as Scheduled II controlled substances because they have a "high potential for abuse" and can cause "severe psychic or physical and or psychological dependence."
Under Federal law, Shire is required to maintain "effective control" against these drugs from falling into the wrong hands. For that reason, Shire and other organizations in the pharmaceutical industry are required under the Controlled Substances Act (CSA), to create internal automated systems to monitor and track suspicious orders of drugs like Adderall and Vyvanse and report them to the DEA.
More on EntSun News
- databahn Announces Subscription Access to Fortune 500 GenAI Deep Dive Sales Intelligence Reports
- AI startup Congero offers instant websites with 24/7 updates - aiming to replace web agencies
- The Recording Academy Extends Invitation to The World's No.1 Superstar™—But He's Not Chasing the Award
- WonderDays Launches the UK's First AI Experience Gift Finder – Gifting Just Got So Much Easier!
- CelluHeal™ Launches Full Line of Advanced Wound Dressings for Online Purchase in the USA, Canada, and Beyond
What's the importance of the corporate integrity agreement? Was this a corporate Coverup?
In September 2014, as Dr. Polito began his work on Suspicious Order Monitoring, Shire agreed to pay $56.5 million as part of a settlement agreement with the Federal Government for alleged violations in their promotion of Adderall and Vyvanse. As part of the settlement, Shire entered into a five-year Corporate Integrity Agreement (CIA).
According to Section III of this Agreement Shire was required to establish and maintain a U.S. Compliance Program. The Agreement requires the chief compliance officer to be responsible for monitoring the day-to-day compliance activities as well as reporting obligations under the CIA. The CIA was signed by then Chief Compliance Officer Caroline H. West.
What was the economic environment at the time of Polito's employment? (mergers and inversions)
In 2014 Shire was engaged with Abbvie in a reverse acquisition for $54 billion. The deal fell through with Shire receiving $1.6 billion for Abbvie's failed attempt. In February 2015 Shire acquired NPS Pharmaceuticals for $5.2 billion. And in June 2016, just as Shire decided to terminate Dr. Polito, Shire acquired Baxalta for $32 billion. Shire was acquired by Takeda in 2019 for $62 billion.
Does this create SEC problems?
The Securities and Exchange Commission (SEC) requires public companies to report information on significant pending lawsuits. An initial review of Shire's 10-k filings for the years 2018- 2021 is silent on Dr. Polito's lawsuit. Whether a lawsuit that alleges violations of DEA's Suspicious Orders regulations and exposes Shire to the type of fines or potential for loss of license qualifies as significant under SEC regulations is something to consider.
Source: Law Office of John McCann, LLC
Filed Under: Financial
0 Comments
Latest on EntSun News
- Opteamix Launches StackRewrite.AI to Transform Enterprise Legacy Modernization
- Planet Maldek: Watcher Files Unseals Explosive New Theory About Mars' True Origins
- DatsJustice Ignites the Industry with New Single "Dead Or Alive" & Announces 2025 Tour Kickoff
- "The Pornified Generation": Dr. Chris Samuels Exposes the Toxic Alliance Between Bro Culture and Pornography That's Rewiring a Generation
- Meet a Scientologist Builds Aussie Dreams with Mike and Jonny Hibbard
- Overwhelmed: Rick Denzien's Stark and Stirring Climate Anthem
- The 2025 ESPY Awards After Party- Presented by Poppi & High Noon
- The Modern Insurance Store Expands Medicare Help Services for Seniors in Cincinnati
- Ironside HR Named Fastest-Growing Staffing Firm for Second Year
- Inframark Continues to Build Its Community Management Capabilities and Multi-Disciplinary Presence in Arizona
- ICAST 2025: The Crystal-Clear Revolution Begins at Booth #3233
- Brindle Pet Supplies Now Carries Badlands Ranch Dog Food in Canada
- $10 Million Allocated to Establish Crypto Treasury Focused on High Value Ethereum (ETH) & Bitcoin (BTC) as Long-Term Holdings for Cybersecurity Leader
- Sing For Your Supper: A Night of Musical Comedy and Drag for a Great Cause
- Cummings Graduate Institute for Behavioral Health Studies Celebrates New DBH Graduates
- $100 to $200 Million Equity Agreement with Top Digital Advisor Bitwise to Power Major Digital Asset Initiative for Bitcoin and Solana: OFA Group
- InSpired Brings World Premiere to the Weinberg Center This October
- New Collaboration Launches Corporate ESG Solution for Responsible Decommissioning and Transparent Reporting
- SlickCashLoan Launches Free Loan Calculator to Help You Plan Monthly Payments
- Hot New Fantasy Series Alert: The Key to Wonderland Captivates Readers with Dark Magic and Twisted Romance